Continuous Glucose Monitoring Using a New Subcutaneous Insulin Protocol for Mild to Moderate Diabetic Ketoacidosis

NANot yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions
Diabetic KetoacidosisHyperglycemia
Interventions
DEVICE

CGM with alerts

"CGM devices will be set to alert the care team when interstitial glucose levels hit 250 mg/dL and 150 mg/dL. Dexcom 7s automatically alert when glucose levels are 55 mg/dL or lower. Nurses will be instructed to check the glucose trends on the CGM device when alerted. They will be asked to check glucose levels with a FSBG according to the following instructions:~1. CGM alerts to interstitial glucose level of 250 mg/dL AND trend indicates rapidly decreasing glucose levels (indicated by double down arrow on Dexcom 7)~2. CGM alerts to interstitial glucose level of 150 mg/dL or less."

Trial Locations (1)

55101

Regions Hospital, Saint Paul

All Listed Sponsors
lead

HealthPartners Institute

OTHER

NCT06693115 - Continuous Glucose Monitoring Using a New Subcutaneous Insulin Protocol for Mild to Moderate Diabetic Ketoacidosis | Biotech Hunter | Biotech Hunter